CA2256977A1 - Methods of extended use oral contraception - Google Patents

Methods of extended use oral contraception Download PDF

Info

Publication number
CA2256977A1
CA2256977A1 CA002256977A CA2256977A CA2256977A1 CA 2256977 A1 CA2256977 A1 CA 2256977A1 CA 002256977 A CA002256977 A CA 002256977A CA 2256977 A CA2256977 A CA 2256977A CA 2256977 A1 CA2256977 A1 CA 2256977A1
Authority
CA
Canada
Prior art keywords
methods
extended use
progestin
estrogen
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002256977A
Other languages
French (fr)
Other versions
CA2256977C (en
Inventor
Gary D. Hodgen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Womens Health Inc
Original Assignee
Medical College of Hampton Roads
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32043766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2256977(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US08/880,419 priority Critical patent/US5898032A/en
Priority to DK98850109T priority patent/DK0911029T3/en
Priority to PT98850109T priority patent/PT911029E/en
Priority to EP98850109A priority patent/EP0911029B1/en
Priority to AT98850109T priority patent/ATE216241T1/en
Priority to ES98850109T priority patent/ES2175650T3/en
Priority to DE69804918T priority patent/DE69804918T2/en
Priority to JP10170390A priority patent/JPH1129481A/en
Priority to NO982815A priority patent/NO982815L/en
Priority to CA002596416A priority patent/CA2596416A1/en
Application filed by Medical College of Hampton Roads filed Critical Medical College of Hampton Roads
Priority to CA002256977A priority patent/CA2256977C/en
Publication of CA2256977A1 publication Critical patent/CA2256977A1/en
Priority to US10/893,795 priority patent/USRE39861E1/en
Publication of CA2256977C publication Critical patent/CA2256977C/en
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Abstract

A method of female contraception involves administering a combination of estrogen and progestin for 60-110 consecutive days in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively. The advantages include less menstrual bleeding, less patient anemia, less total exposure to medication, higher compliance rates and more lifestyle convenience for patients.
CA002256977A 1997-06-23 1998-12-23 Methods of extended use oral contraception Expired - Fee Related CA2256977C (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
US08/880,419 US5898032A (en) 1997-06-23 1997-06-23 Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE69804918T DE69804918T2 (en) 1997-06-23 1998-06-15 Very low-dose oral contraceptive with less menstrual bleeding and delayed effects
PT98850109T PT911029E (en) 1997-06-23 1998-06-15 ORAL CONTRACEPTIVES IN ULTRA-LOW DOSES WITH LESS MENSTRUAL HEMORRHAGES AND WITH PROLONGED EFFICACY
EP98850109A EP0911029B1 (en) 1997-06-23 1998-06-15 Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
AT98850109T ATE216241T1 (en) 1997-06-23 1998-06-15 VERY LOW DOSE ORAL CONTRACEPTIVE WITH LESS MENSTRUAL BLEEDING AND DELAYED EFFECT
ES98850109T ES2175650T3 (en) 1997-06-23 1998-06-15 ULTRA LOW ORAL DOSE ANTI-CONTRACEPTIVES WITH LESS MONTHLY HEMORRAGY AND MAINTAINED EFFECTIVENESS.
DK98850109T DK0911029T3 (en) 1997-06-23 1998-06-15 Oral contraceptives with ultra-low dose that have prolonged activity and induce less menstrual bleeding
JP10170390A JPH1129481A (en) 1997-06-23 1998-06-17 Ultra low dosage contraceptive decreasing bleeding at menses and having sustained activity
NO982815A NO982815L (en) 1997-06-23 1998-06-18 Ultra-low dose oral contraceptives with less menstrual bleeding and sustained efficacy
CA002596416A CA2596416A1 (en) 1998-12-23 1998-12-23 Methods of extended use oral contraception
CA002256977A CA2256977C (en) 1997-06-23 1998-12-23 Methods of extended use oral contraception
US10/893,795 USRE39861E1 (en) 1997-06-23 2004-07-19 Methods of extended use oral contraception

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/880,419 US5898032A (en) 1997-06-23 1997-06-23 Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
CA002256977A CA2256977C (en) 1997-06-23 1998-12-23 Methods of extended use oral contraception

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002596416A Division CA2596416A1 (en) 1998-12-23 1998-12-23 Methods of extended use oral contraception

Publications (2)

Publication Number Publication Date
CA2256977A1 true CA2256977A1 (en) 2000-06-23
CA2256977C CA2256977C (en) 2008-11-25

Family

ID=32043766

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002256977A Expired - Fee Related CA2256977C (en) 1997-06-23 1998-12-23 Methods of extended use oral contraception

Country Status (10)

Country Link
US (2) US5898032A (en)
EP (1) EP0911029B1 (en)
JP (1) JPH1129481A (en)
AT (1) ATE216241T1 (en)
CA (1) CA2256977C (en)
DE (1) DE69804918T2 (en)
DK (1) DK0911029T3 (en)
ES (1) ES2175650T3 (en)
NO (1) NO982815L (en)
PT (1) PT911029E (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19549264A1 (en) * 1995-12-23 1997-06-26 Schering Ag Contraception procedure and kit
WO2001030355A1 (en) * 1999-10-25 2001-05-03 Laboratoire Theramex Contraceptive medicine based on a progestational agent and an oestrogen and preparation method
FR2754179B1 (en) 1996-10-08 1998-12-24 Theramex NOVEL HORMONONAL COMPOSITION AND ITS USE
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6251956B1 (en) 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
DE19739916C2 (en) 1997-09-11 2001-09-13 Hesch Rolf Dieter Use of a combination of a progestogen and an estrogen for the continuous inhibition of ovulation and possibly simultaneous treatment and / or prophylaxis of tumors of the mammary glands
EP1148884A4 (en) * 1998-11-12 2003-06-11 Warner Chilcott Lab Ireland Lt Graduated progestin contraceptive
US7297688B2 (en) 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
DE10045380A1 (en) * 2000-09-14 2002-04-04 Schering Ag Contraception procedure and dosage form
EP1406633B1 (en) * 2001-06-18 2011-10-05 Noven Pharmaceuticals, Inc. Enhanced drug delivery in transdermal systems
US20030018018A1 (en) * 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
WO2003049744A1 (en) * 2001-12-05 2003-06-19 Barr Laboratories, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
CN101001631B (en) * 2003-07-16 2014-08-06 特卫华妇女健康有限公司 Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
CN1863716B (en) * 2003-09-04 2010-10-27 药品设计有限公司 Case with pill receiving sleeves for storing and dispensing pills
BRPI0414945A (en) * 2003-10-01 2006-11-07 Janssen Pharmaceutica Nv extended three-phase contraceptive regimens
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
ES2397983T3 (en) 2004-03-19 2013-03-12 Warner Chilcott Company, Llc Long-cycle multiphase oral contraceptive procedure
DE102004019743B4 (en) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Multiphase preparation for contraception based on natural estrogen
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
DE102004026670A1 (en) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonal contraceptive containing a combination of ethinylestradiol and chlormadinone acetate
DE102004026679A1 (en) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonal contraceptive containing a combination of ethinylestradiol and chlormadinone acetate
DE102004026671A1 (en) 2004-05-28 2005-12-15 Grünenthal GmbH Dosage form for hormonal contraception
US8501720B2 (en) * 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20060135496A1 (en) * 2004-10-07 2006-06-22 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
EP1655031A1 (en) 2004-10-08 2006-05-10 Schering AG Use of dienogest in fixed extended cycle hormonal contraceptives
US20060079491A1 (en) * 2004-10-08 2006-04-13 Andreas Sachse Method of female hormonal contraception using a fixed extended cycle hormonal preparation containing dienogest and ethinyl estradiol
US7704984B2 (en) * 2005-04-22 2010-04-27 Warner Chilcott Company, Llc Extended estrogen dosing contraceptive regimen
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1983999A4 (en) * 2006-01-27 2010-10-20 Teva Womens Health Inc Regimens for treatment of conditions related to estrogen deficiency
CA2640520C (en) * 2006-03-02 2014-04-22 Warner Chilcott Company, Inc. Extended cycle multiphasic oral contraceptive method
EP1930010A1 (en) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Application of estradiol valerate or 17ß-estradiol in combination with dienogest for oral therapy to maintain and/or increase the female libido
DE202007019049U1 (en) * 2007-11-05 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Use of a gestagen in combination with an estrogen for the prophylaxis of lactose intolerance in oral contraception
US20100120707A1 (en) * 2008-09-16 2010-05-13 Playtex Products, Llc Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same
US9192614B2 (en) 2008-10-08 2015-11-24 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
EP2343963B1 (en) 2008-10-08 2019-04-10 Agile Therapeutics, Inc. Transdermal delivery
ES2795455T3 (en) 2008-10-08 2020-11-23 Agile Therapeutics Inc Transdermal delivery
WO2010111488A1 (en) 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery
US20180125860A1 (en) * 2015-05-18 2018-05-10 Agile Therapeutics, Inc. Contraceptive Compositions and Methods for Improved Efficacy and Modulation of Side Effects
WO2023037264A1 (en) * 2021-09-07 2023-03-16 Millicent Pharma Limited Contraceptive regimen including reduced level of estrogen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145416A (en) 1976-06-23 1979-03-20 Schering, A.G. Novel agents and novel methods for treatment of climacteric disturbances
US4390531A (en) * 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US4962098A (en) 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5098714A (en) * 1989-11-16 1992-03-24 Alza Corporation Osmotic, oral dosage form for fertility control
MX9301121A (en) 1992-03-02 1993-09-01 Schering Ag METHOD AND EQUIPMENT FOR ORAL CONTRACEPTION AND REGULATION OF MENSTRUATION WITH ESTROGEN / PROGESTIN / ANIPROGESTIN.
DE4344462C2 (en) 1993-12-22 1996-02-01 Schering Ag Composition for contraception
DE4411585A1 (en) * 1994-03-30 1995-10-05 Schering Ag Combined pharmaceutical preparation for hormonal contraception
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
DE19525017A1 (en) * 1995-06-28 1997-01-02 Schering Ag Pharmaceutical combination preparation, kit and method for hormonal contraception
DE19531936A1 (en) 1995-08-17 1997-02-20 Schering Ag Combination preparation for contraception, containing kits and a method using them
AU3888597A (en) 1996-07-26 1998-02-20 American Home Products Corporation Oral contraceptive
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (en) 1997-09-11 2001-09-13 Hesch Rolf Dieter Use of a combination of a progestogen and an estrogen for the continuous inhibition of ovulation and possibly simultaneous treatment and / or prophylaxis of tumors of the mammary glands
US6214815B1 (en) 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US20030018018A1 (en) 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
WO2003049744A1 (en) 2001-12-05 2003-06-19 Barr Laboratories, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US20030219471A1 (en) 2002-03-11 2003-11-27 Caubel Patrick Michel Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
US7772219B2 (en) 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20040251301A1 (en) 2003-05-05 2004-12-16 Niemann Amy C. Device for calculating anticipated days for menstruation
US20040222123A1 (en) 2003-05-06 2004-11-11 Barr Laboratories, Inc. Kit for pharmaceuticals
CN101001631B (en) 2003-07-16 2014-08-06 特卫华妇女健康有限公司 Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
CN1863716B (en) 2003-09-04 2010-10-27 药品设计有限公司 Case with pill receiving sleeves for storing and dispensing pills
BRPI0414945A (en) 2003-10-01 2006-11-07 Janssen Pharmaceutica Nv extended three-phase contraceptive regimens

Also Published As

Publication number Publication date
DE69804918D1 (en) 2002-05-23
EP0911029A3 (en) 2000-03-29
CA2256977C (en) 2008-11-25
EP0911029A2 (en) 1999-04-28
USRE39861E1 (en) 2007-09-25
PT911029E (en) 2002-09-30
DE69804918T2 (en) 2002-11-07
DK0911029T3 (en) 2002-06-17
JPH1129481A (en) 1999-02-02
ES2175650T3 (en) 2002-11-16
ATE216241T1 (en) 2002-05-15
US5898032A (en) 1999-04-27
NO982815D0 (en) 1998-06-18
EP0911029B1 (en) 2002-04-17
NO982815L (en) 1998-12-28

Similar Documents

Publication Publication Date Title
CA2256977A1 (en) Methods of extended use oral contraception
JP2848919B2 (en) Medication for the treatment of premenopausal hormonal abnormalities, for menopausal hormone replacement therapy, for the treatment of androgen-induced disorders and for contraception
JP6134491B2 (en) Management of broken bleeding in extended hormonal contraception
AU7537987A (en) Combination dosage form for pre-menopausal women
CA2222133A1 (en) Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
CA2356747A1 (en) Triphasic oral contraceptive
CA2179728A1 (en) Composition for a contraceptive comprising an estrogen and a gestagen
NZ333750A (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
HUP9900612A2 (en) Novel hormonal medicaments and use thereof for correcting oestrogen deficiencies
NZ333862A (en) Triphasic oral contraceptive method and kit comprising a combination of progestin and estrogen
AU4043597A (en) Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen
Robb-Nicholson By the way, doctor. I am 47 and have been taking Loestrin 1/20 for the past seven months. After the first month, I ceased having periods, which my gynecologist says is typical. Could you comment on why this happens and whether I am putting myself at increased risk for uterine cancer?
MXPA06009740A (en) Extended cycle multiphasic oral contraceptive method

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20161223